I. INTRODUCTION
Peripheral T-cell lymphomas (PTCLs) comprise a variety of uncommon and overall rare malignancies derived from mature (post-thymic) T cells and NK cells, altogether accounting for less than 15% of all non-Hodgkin lymphomas worlwide. 1 The WHO approach to lymphoma classification relies on a combination of morphologic, immunophenotypic, genetic and clinical features, and attempts to correlate disease entities with a normal cellular counterpart. 2 While these principles have led to the comprehensive delineation of B-cell lymphoma entities, their application to NK/T-cell-derived neoplasms is hampered by several difficulties. Table 1 ). The normal cell counterparts of the NK and T-cell lineages involved in innate and adaptive immunity, constitute a complex system with numerous functional subsets displaying marked phenotypic diversity and also evidence of plasticity. Although there is increasing evidence that the cell of origin is a major determinant for the delineation of several PTCL entities 3 , 4 , 5 , compounded by the concurrent rarity and diversity of PTCLs hampering the collection of homogeneous cohorts of patients, the heterogeneity of the pathological samples, the absence of cell lines representative of the major entities, and the lack of good animal models. In recent years, however, novel insights have been gained from genome-wide profiling analyses. 4, [7] [8] [9] [10] [11] [12] [13] Here, we will summarize the current knowledge on the pathobiological features of selected peripheral NK/T-cell neoplasms. The review will be focused on selected disease entities manifesting as tissue infiltrates primarily in extranodal sites and lymph nodes.
II. PRIMARILY EXTRANODAL PTCL ENTITIES
Not taking into consideration the most common forms of primary cutaneous T-cell lymphomas (Mycosis fungoides/Sezary syndrome and primary cutaneous CD30+ T-cell lymphoproliferations) that have not been incorporated systematically into the recent epidemiological studies, PTCL entities with primary extranodal presentation are overall less common than nodal PTCLs, especially in Europe and North America ( Table 2) . 6 It is noteworthy that neoplasms derived from cells of the innate immune system (mostly NK-cell and gamma-delta T-cell lymphomas) have a specific tropism for extranodal sites. Remarkably, the different extranodal PTCL entities -defined primarily by their clinical features and immunophenotype -share several common features 14, 15 Within each entity, the cytomorphology of the tumors is highly variable, in contrast to a virtually constant cytotoxic profile. Clinically, lymph node involvement is rare, dissemination to other extranodal sites is common, the occurrence of a hemophagocytic syndrome is relatively frequent and the clinical evolution of the patients is usually aggressive while the present therapeutic strategies are limited. Immune stimulation by 
A. Extranodal NK/T-cell lymphoma, nasal type
Extranodal NK/TCL is not exceptional in western countries, but predominantly affects middle-aged men in Asia, Mexico and South America. 16 It presents as tumors or destructive lesions in the nasal cavity, maxillary sinuses or palate, previously referred to as "lethal midline granuloma". Despite a localized presentation in most patients, the prognosis is poor with around 40-50% 5-year survival rate and tendency for local relapses or dissemination to other extranodal sites, such as the skin.
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Extranodal NK/TCL is morphologically heterogeneous with a cytological spectrum ranging from monomorphic small/medium-sized to large cell lymphomas, and is characterized by frequent features of angioinvasion and angiocentrism, and common necrosis, accounting for frequent diagnostic difficulties on small biopsies ( In most cases, the tumor cells do not express the T-cell receptor (TCR)/CD3 complex at the cell membrane and have TCR genes in a germline configuration, consistent with a NK-cell derivation. A small proportion of cases with expression of an γδ or αβ TCR, have clonal TCR genes rerrangements and likely derive from cytotoxic T lymphocytes, hence the "NK/T-cell" terminology. 2 The pathogenesis of extranodal NKTCL remains unclear, but several lines of evidence point at EBV as a major player. EBV is clonally present in an episomal form in the tumour cells and exerts oncogenic effects through the production of cytokines such as IL-9 and IL-10. 18 EBV-induced upregulation of IP10/MIP2 chemokines may contribute to vascular damage and secondary necrosis. 19 while TNF α production may explain the common hemophagocytic syndrome. activation of PDGFRA, and of the AKT, Janus kinase-signal transducers and activators of transcription, and nuclear factor-kappaB pathways, which might represent targets for the development of novel therapeutic options. 22, 23 Several mechanisms have been evidenced that may contribute to the poor response of extranodal NKTCL to chemotherapy: deregulation of apoptotic pathways due to FAS gene alterations and TP53 mutations 24, 25 , expression of the multidrug resistance (MDR) 1 gene product P-glycoprotein, immune escape by defective CD94/NKG2A NK-cell receptors 26 .
Lymphomas morphologically, and phenotypically similar to the nasal NKTCL, may present in other localizations, especially in the skin, gastrointestinal tract or testis.
These "extranasal NK/T cell lymphomas" tend to have a more adverse clinical outcome than nasal cases.
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B. Subcutaneous panniculitis-like T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare entity which typically presents on the extremities or trunk as multiple subcutaneous nodules. 3, 28 It shows a broad age range. Nodal involvement is rare. By definition in the last he disease is now restricted to those tumours with an α/β origin. CD8+, CD56-, with a cytotoxic immunophenotype. They are EBV-negative.
SPTCL as currently described and restricted to cases with an αβ T-cell phenotype -have a favorable prognosis with around 80% 5-year overall survival, which is in contrast to the dismal outcome of cases of γδ derivation   as  discussed below namely hepatosplenic T-cell lymphoma and primary cutaneous γδ T-cell lymphomas.
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A γδ T-cell phenotype may be occasionally encountered occasionally in cases otherwise not fulfilling the criteria for these specifc γδ entities, especially in PTCLs arising in mucosal sites. Irrespective of the classification, they usually pursue a very aggressive course.
Hepatosplenic T-cell lymphoma
Hepatosplenic T-cell lymphoma (HSTL) was first described in 1990 as a rare form of γδ T-cell lymphoma with distinct clinico-pathologic features, in two young male patients with a fatal outcome. 30 Most cases are of γδ derivation, a mention included in the original designation of the entity, but since similar cases with a αβ phenotype have been described 31, 32 the designation "hepatosplenic T-cell lymphoma" is now preferred.
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The clinical features are uniform. Most patients are young individuals (median age 30s) with a male predominance. They present with systemic symptoms, hepatosplenomegaly, and thrombocytopenia in the absence of lymphadenopathy.
They typically experience rapid relapse and a fatal outcome after initial complete response to chemotherapy.
The lymphoma cells are monomorphic, small to medium sized with moderately abundant pale cytoplasm and display sinuosidal infiltration in the spleen, liver, and sinusal localization in the bone marrow (Figure 4) . Figure 3B) . 33, 34 The TCR/CD3 complex is expressed at lower levels than in normal γδ T cells.
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At the genetic level, HSTL is associated in most cases with isochromosome 7q, but how this aberration is related to the pathogenesis of the disease is unkown. 36 HSTL is typically not associated with EBV. The gene expression signature of HSTL is rather homogeneous and distinct from that of non-hepatosplenic γδ T cell lymphomas. 
Primary cutaneous gamma-delta T-cell lymphoma
Primary cutaneous γδ T-cell lymphoma has been introduced as a provisional entity in T-cell lymphomas frequently also display both an epidermal and dermal infiltration.
3,
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In line with their γδ T-cell derivation, the lymphoma are usually CD4-CD8-This immunophenotype is also distinct from that of SPTCL (CD3+ CD8+, CD56-,
It has been proposed that these cutaneous γδ T cell lymphoma with panniculitis-like changes may be part of the spectrum of "mucocutaneous γδ γδ γδ γδ T cell ETL is not associated with EBV. The neoplastic cells express the mucosal homing receptor CD103 characteristic of intra-epithelial lymphocytes, are usually CD3+
CD5-CD4-CD8-αβ T cells with an activated cytotoxic profile. CD30 is often partially expressed by the neoplastic cell population. Interleukin-15 (IL-15), a proinflammatory cytokine upregulated in the epithelium of patients with celiac disease, is thought to play a major role in promoting the malignant transformation of IEL, by triggering an antiapoptotic pathway in IEL. 53 54 At the genomic level, complex chromosomal gains at 9q31.3-qter or deletions of 16q21.1 are found in the majority of the cases, but gains or partial trisomy of 1q22-44 might be more specific. Gains at 5q are also frequent.
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ETL type II
A subset of so-called ETL, appears to be unrelated to celiac disease. They overall comprise a minority of ETL, but represent the major ETL type in countries where celiac disease is not prevalent. The pathological features of these ETL qualified as type II, are also distinct from those of the classical type. Histologically, ETL type II comprises a monomorphic proliferation of medium-sized cells, usually has no or little necrosis, and few admixed inflammatory cells (Figure 6C-6D 
III. PRIMARILY NODAL PTCL ENTITIES
Four PTCL entities account for the majority of PTCL cases with nodal presentation :
angioimmunoblastic T-cell lymphoma (AITL) ; anaplastic large cell lymphoma (ALCL), ALK-positive ; ALCL, ALK-negative ; and peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS). AITL has distinctive pathological features. ALKpositive and ALK-negative ALCL previously viewed as two variants of the same disease entity, are now considered as as distinct disease entities. 2 PTCL, NOS is an exclusion diagnosis for cases not fulfilling the criteria for any of the « specific » PTCL types.
A. Angioimmunoblastic T-cell lymphoma
AITL, the second most common PTCL wordwide, is mostly prevalent in Europe and
North America where it accounts for 25-30% of the cases. 1 The disease which affects elderly adults 59 Figure 7B ). 60 61 These patterns are thought to reflect morphologic evolution of the disease rather than clinical progression 60, 61 , 62, 63 The lymphoma cells are medium-sized with round or slightly irregular nuclei, clear cytoplasm and distinct cell membranes ( Figure 7C ). They are often Table 3 ). The most common is the t(2;5)(p23;q35), which fuses the ALK to the nucleophosmin gene (NPM) on chromosome 5. All translocations juxtapose the cytoplasmic catalytic domain of ALK to a partner protein, forming a chimeric fusion protein which induces constitutive ALK tyrosine kinase activation (reviewed in 90, 91 ).
The type of translocation determines the subcellular distribution of upregulated ALK (Table 3) . In addition to expression of CD30 and ALK (Figure 9B) , the vast majority of In vitro, constitutively activated ALK chimeras induce cellular transformation, enhance cell proliferation and survival (for review, see 91 , 96 ). The oncogenic proprties of ALK are mediated by interaction with downstream molecules that engage intracellular signalling pathways, among which the JAK3-STAT3 pathway is of prime importance, as exemplified by the fact that in ALCL cell lines, two thirds of ALKregulated genes are concordantly dependent on STAT3 expression. 97 The transcription factor C/EBPbeta which is part of the molecular signature os ALK-positive ALCL, also plays an important role as it is absolutely necessary to induce cell transformation and/or to sustain the growth and survival of ALK-positive ALCL cells. 98, 99 In vivo, however, the NPM-ALK fusion transcript has been detected at low levels in reactive lymph node and normal peripheral blood samples of healthy individuals, suggesting additional cofactors. positive. 113 Compared to other PTCL, NOS, the lymphoepithelioid variant tends to remain confined to lymph nodes with infrequent extranodal involvement 114 , and may be associated with an overall better prognosis. The follicular variant of PTCL, NOS named after a pattern of growth intimately related to follicular structures, has been recently described. It comprises cases with a truly follicular pattern, mimicking follicular lymphoma, 115 T-cell lymphomas with a perifollicular growth pattern, 116 or involving expanded mantle zones. 117, 118 In view of the T FH phenotype and overlapping features with AITL in some cases, the possible relationship to AITL is questionable. 115, 118, 119 A recurrent chromosomal translocation t(5;9)(q33;q22)
involving ITK and SYK tyrosine kinase, has been described in association with follicular PTCLs, 120 but is otherwise rarely found in non-follicular PTCLs, which may support the concept of a distinct subtype. Interestingly, however, overexpression and activation of SYK appear to be a feature common to most PTCLs, which potentially represents a novel therapeutic target. 121, 122 Attempts to subclassify PTCL-NOS according to immunological features (CD4 versus CD8 subsets, Th1 versus Th2 helper function, differentiation stage) have overall not proven meaningful. 123 , 124 At the molecular level, PTCLs, NOS are most closely related to activated than resting CD4 or CD8+ T cells, and are characterized by deregulation of genes related to proliferation, apoptosis, cell adhesion, matrix remodeling. 10 Interestingly, some cases classified as PTCL, NOS based on their pathological features, have been found to harbor imprints of traces of the T FH signature, NOS, suggesting that a subset of PTCL, NOS might be related to AITL, and/or that the AITL spectrum might be wider than suspected. 125 Iqbal et al. PTCLs, NOS frequently harbor complex karyotypes, and their genomic imbalances differ from those observed in AITL and ALCL. [128] [129] [130] Oncogenic alterations are poorly characterized. Gene expression profiling identified the PDGFRalpha as a potential novel therapeutic target in PTCL, NOS, as it is overexpressed and activated in most cases. 10, 131 Overexpression of NF-kappaB pathway genes was found in one study to correlate with a better outcome. 8 Conversely, overexpression of a proliferation signature correlated with an adverse prognosis, and appears to be inversely related to signature clusters related to inflammatory response and reflective of an abundant reactive background in the tumor.
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IV. CONCLUDING REMARKS
Novel insights to the pathobiology of PTCLs have been gained over the past few years, stemming from epidemiological studies, clinico-pathological analyses and high-throughput molecular profiling studies. Significantly, the demonstration of hte cellular derivation of AITL from TFH cells represents a major step in the understanding of the biology this disease entity, and may also potentially open the way to the development of targeted therapies. Whether evidence for a TFH derivation would become a specific defining feature for this entity remains to be determined, but it is likely that the spectrum of AITL will expand. Yet, the large group of PTCL without specification remains poorly understoood and the clinical relevance of subgroups identified within that large entity has to be clarified. Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) 26%
Angioimmunoblastic T-cell lymphoma (AITL) 18%
Extranodal NK/T-cell lymphoma, nasal type 10%
Adult T-cell lymphoma/leukemia (HTLV1-positive) 10%
Anaplastic large cell lymphoma, ALK-positive 7%
Anaplastic large cell lymphoma, ALK-negative 5%
Enteropathy-associated T-cell lymphoma 5%
Primary cutaneous anaplastic large cell lymphoma 2%
Hepatosplenic T-cell lymphoma 1%
Subcutaneous panniculitis-like T-cell lymphoma 1%
Other entities and unclassifiable cases 14% 
